Access to the DLBCL subtype Classification tool is restricted to a limited set
Access the Classification Tool using your NIH/Federated login
Access the Classification Tool using a local login/password
Lymph2Cx Portal Users Guide (Updated Oct 2, 2014) in PDF (Adobe Reader) format
Disclaimer: This test is designed to be used on FFPE samples that
have been confirmed by Pathologists to be of the DLBCL subtype with at least
60% tumor content, and have been processed according to the Nanostring SOP.
Other samples may produce unexpected or inaccurate results. Although some
quality control is incorporated into the algorithm it is recommended that
users additionally exclude samples that have been flagged by the NanoString
nSolver Analysis software as being of poor quality, or otherwise appear as
outliers. This tool has not been evaluated by the FDA or any other regulatory
agency, and is not intended for clinical use.
|Direct questions/support issues to
NIH BioInformatics support provided by
We can be contacted by